Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Baxter
Covington
Chinese Patent Office
Accenture
Citi
AstraZeneca
Farmers Insurance
Moodys
Cipla

Generated: February 21, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,658,590

« Back to Dashboard

Summary for Patent: 5,658,590
Title: Treatment of attention-deficit/hyperactivity disorder
Abstract:Tomoxetine, a norepinephrine uptake inhibitor, is used to treat attention-deficit/hyperactivity disorder.
Inventor(s): Heiligenstein; John H. (Indianapolis, IN), Tollefson; Gary D. (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:08/371,341
Patent Claims: 1. A method of treating attention-deficit/hyperactivity disorder comprising administering to a patient in need of such treatment an effective amount of tomoxetine.

2. A method of claim 1 wherein the predominantly inattentive type of attention-deficit/hyperactivity disorder is treated.

3. A method of claim 1 wherein the predominantly hyperactive-impulsive type of attention-deficit/hyperactive disorder is treated.

4. A method of claim 1 wherein the combined type of attention-deficit/hyperactivity disorder is treated.

5. A method of claim 1 wherein the patient is an adult.

6. A method of claim 5 wherein the predominantly inattentive type of attention-deficit/hyperactivity disorder is treated.

7. A method of claim 5 wherein the predominantly hyperactive-impulsive type of attention-deficit/hyperactive disorder is treated.

8. A method of claim 5 wherein the combined type of attention-deficit/hyperactivity disorder is treated.

9. A method of claim 1 wherein the patient is an adolescent.

10. A method of claim 9 wherein the predominantly inattentive type of attention-deficit/hyperactivity disorder is treated.

11. A method of claim 9 wherein the predominantly hyperactive-impulsive type of attention-deficit/hyperactive disorder is treated.

12. A method of claim 9, wherein the combined type of attention-deficit/hyperactivity disorder is treated.

13. A method of claim 1 wherein the patient is a child.

14. A method of claim 13 wherein the predominantly inattentive type of attention-deficit/hyperactivity disorder is treated.

15. A method of claim 13 wherein the predominantly hyperactive-impulsive type of attention-deficit/hyperactive disorder is treated.

16. A method of claim 13 wherein the combined type of attention-deficit/hyperactivity disorder is treated.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Express Scripts
Johnson and Johnson
US Department of Justice
Queensland Health
Accenture
Baxter
Teva
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot